Corona Remedies debuted on Dalal Street with a significant 38.42% premium, opening at Rs 1,470 on NSE and Rs 1,452 on BSE. The Rs 655 crore IPO, entirely an offer for sale, was oversubscribed 144.5 times, highlighting strong investor confidence in its business model and niche market leadership.